Drug Type Prophylactic vaccine, Dendritic cell vaccine |
Synonyms DC-ATA, DCV |
Target |
Mechanism SARS-CoV-2 S protein modulators(SARS-CoV-2 S protein modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization ![]() |
Active Organization- |
Inactive Organization ![]() |
Drug Highest PhasePendingPhase 2/3 |
First Approval Date- |
Regulation- |
Start Date01 Jan 2023 |
Sponsor / Collaborator ![]() |
Start Date14 Apr 2021 |
Sponsor / Collaborator ![]() [+1] |
Start Date07 Dec 2020 |
Sponsor / Collaborator ![]() [+1] |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | US | AiVita Biomedical, Inc.Startup | 08 Dec 2020 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1/2 | 176 | qhnxlsfyxy(hbrruhvjtr) = tgfkntwoye pvbwbutcqg (utfqvkjuvj ) View more | Positive | 26 Aug 2022 | |||
Phase 2 | 145 | zfsoqaakoh(qmbkagnngd) = dneconjgzd fwduqrqxwd (mxftqdaubt ) View more | Positive | 13 Sep 2021 |